Johnson & Johnson Completes Acquisition of Intra-Cellular Therapies
US-based Johnson & Johnson (NYSE: JNJ) announced the completion of its acquisition of fellow American...
Johnson & Johnson
Bio-Thera Solutions Inks Licensing Deal with Dr. Reddy’s for Biosimilar Commercialization
Guangzhou-based Bio-Thera Solutions (SHA: 688177) has entered into a licensing agreement with India-headquartered Dr. Reddy’s...
Johnson & Johnson Pledges USD55 Billion for US Expansion, Focusing on Manufacturing and R&D
US giant Johnson & Johnson (J&J, NYSE: JNJ) has committed to investing over USD 55...
Johnson & Johnson’s Tremfya Gains FDA Approval for Crohn’s Disease Treatment
US pharmaceutical giant Johnson & Johnson (J&J, NYSE: JNJ) has announced receiving clearance from the...
Johnson & Johnson’s Nipocalimab Receives FDA Fast Track Designation for Sjögren’s Disease
US giant Johnson & Johnson (J&J; NYSE: JNJ) announced receiving Fast Track designation (FTD) from...
Bio-Thera Solutions’ BAT2506 Biosimilar Accepted for Review by China’s NMPA
China-based Bio-Thera Solutions Inc. (SHA: 688177) announced that a market filing for its BAT2506, a...
Legend Biotech Reports Strong Q4 and Full Year 2024 Financial Results
China-based Legend Biotech Corporation (NASDAQ: LEGN) released its Q4 and full-year 2024 financial results, highlighting...
Genmab’s HexaBody-CD38 Clinical Development Halted After J&J Opt-Out
Denmark-based Genmab A/S (NASDAQ: GMAB) announced that US giant Johnson & Johnson (J&J, NYSE: JNJ)...
Johnson & Johnson Officially Launches Spravato in China for Depression Treatment
US giant Johnson & Johnson (J&J; NYSE: JNJ) officially launched Spravato (esketamine) nasal spray in...
GE Healthcare’s China CEO Yihao Zhang to Retire, Will Song Named Successor
US medical device and life sciences giant GE Healthcare Technologies Inc. (NASDAQ: GEHC) announced the...
J&J MedTech Launches Locally Produced HARMONIC 7s Scalpel in China
Johnson & Johnson MedTech, a US-based healthcare giant, announced the official launch of its HARMONIC...
J&J’s Tremfya Wins NMPA Approval for Crohn’s Disease Treatment
Johnson & Johnson (J&J, NYSE: JNJ) announced that its Tremfya (guselkumab) has received marketing approval...
Sandoz Launches Pyzchiva Biosimilar of J&J’s Stelara in US
Switzerland-based Sandoz (SWX: SDZ) announced the launch of Pyzchiva, a biosimilar version of Johnson &...
J&J’s Tremfya Meets All Endpoints in Phase III UC Study, Eyes FDA Approval for SC Induction
U.S. pharmaceutical giant Johnson & Johnson (J&J, NYSE: JNJ) presented positive results from the Phase...
Sanofi and J&J’s E. coli Vaccine Fails Phase III Study
France-based Sanofi (NASDAQ: SNY) and US giant Johnson & Johnson’s (J&J, NYSE: JNJ) vaccine candidate...
J&J Considers Selling Stroke Care Business Cerenovus for USD1-1.5 Billion
US giant Johnson & Johnson (J&J, NYSE: JNJ) is reportedly considering selling its stroke care...
Hengrui Pharma’s BD Head Dr. Chen Dong Departs for AbbVie’s External Innovation Role
Dr. Chen Dong, Vice President and China Head of BD at Jiangsu Hengrui Pharmaceuticals Co.,...
Huadong Medicine’s Biosimilar SaiYueXin Seeks NMPA Approval for Crohn’s Disease
Huadong Medicine Co., Ltd (SHE: 000963) announced that another indication approval filing for its SaiYueXin,...
J&J Innovative Medicine China Appoints New General Manager and Oncology VP
Johnson & Johnson (J&J, NYSE: JNJ) Innovative Medicine China has recently made two major appointments...
Bio-Thera Solutions Licenses BAT2506 to Intas Pharmaceuticals for US Market
China-based Bio-Thera Solutions Inc. (SHA: 688177) announced that it has entered into a licensing agreement...